Lyrica Expected to Face Generic Onslaught by Year’s End as Patent Ruled Invalid

A slew of generic contenders will likely flock to Pfizer’s top-seller pain medicine Lyrica (pregabalin) late this year now that the Japan Patent Office (JPO) has invalidated its application patent after an IP battle that lasted over three and a...read more